Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Patricia A. Lodge"'
Autor:
Steven J. Monahan, Michael L. Salgaller, Ronnie A. Childs, Patricia A. Lodge, Alton L. Boynton, Gerald P. Murphy, Anil Sehgal, Joanne G. McLean
Publikováno v:
Journal of Immunotherapy. 22:346-355
Antigen-specific immunotherapy of cancer depends on a consistent source of well-defined protein antigen. Production of recombinant protein offers the obvious solution to this problem but few comparisons of recombinant and native proteins in cellular
Publikováno v:
Journal of Surgical Oncology. 68:122-138
Cellular and cytokine adjuvants, often immune effector cells and soluble factors, respectively, are supplemental and/or follow-up treatments of human origin for cancer patients who have unsatisfactory clinical responses to conventional chemotherapy,
Autor:
Haakon Ragde, Gerald P. Murphy, Alton L. Boynton, Mary Rogers, Joanne G. McLean, G.M. Kenny, Ben A. Tjoa, Douglas J. Loftus, Michael L. Salgaller, Patricia A. Lodge
Publikováno v:
The Prostate. 35:144-151
BACKGROUND In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings. METHODS Phase II s
Autor:
Subramaniam Sriram, Patricia A. Lodge
Publikováno v:
Journal of Leukocyte Biology. 60:502-508
Microglia are the resident macrophages of the brain and as such are active participants in immune responses in the central nervous system. Normal resting microglia express low levels of MHC class I and class II antigens and do not produce proinflamma
Publikováno v:
Annals of Neurology. 36:734-740
Characterization of T cells responding to autoantigens is central to understanding autoimmune disease. We have used somatic mutation at the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene as an index of T-cell amplification in vivo. With t
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 36(2)
Dendritic cells (DCs) are increasingly prepared in vitro for use in clinical trials of human disease. Their utility in experimental immunotherapy has driven significant advances in the manufacture of these cells. Thus it has become imperative that, i
Publikováno v:
Journal of immunological methods. 285(2)
The utility of dendritic cells (DCs) in experimental immunotherapy has driven significant advances in the manufacture of these cells. They are increasingly prepared in vitro for use in clinical trials of human disease, particularly cancer. Thus, it h
Autor:
Gopi Shankar, Patricia A. Lodge
Publikováno v:
Expert opinion on biological therapy. 2(4)
Autor:
Monica Toth, Alton L. Boynton, Yaling Zhou, Patricia A. Lodge, Steven J. Monahan, M.Shane Hamman, Michael L Salgaller
Publikováno v:
Biochemical and biophysical research communications. 290(2)
Identifying immunogenic tumor antigens plays a critical role in developing efficient diagnostic and therapeutic strategies for treatment of cancer. Using a recently developed technology, serological identification of antigens by recombinant expressio
Autor:
Benjamin A. Tjoa, Michael L. Salgaller, Alton L. Boynton, Patricia A. Lodge, Gerald P. Murphy
Publikováno v:
CA: a cancer journal for clinicians. 49(2)
Dendritic cells are unique in their ability to stimulate naive T cells. These investigators have developed a prostate cancer vaccine using autologous dendritic cells as a vehicle to present prostate antigens to T cells in vivo.